Management Inc. Opaleye Net Worth

The estimated Net Worth of Management Inc. Opaleye is at least $13.2 Million dollars as of 9 September 2024. Management Opaleye owns over 61,992 units of TELA Bio stock worth over $140,184 and over the last 9 years Management sold TELA stock worth over $13,051,972.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Management Opaleye TELA stock SEC Form 4 insiders trading

Management has made over 102 trades of the TELA Bio stock since 2016, according to the Form 4 filled with the SEC. Most recently Management sold 61,992 units of TELA stock worth $114,065 on 9 September 2024.

The largest trade Management's ever made was selling 4,764,008 units of TELA Bio stock on 10 November 2023 worth over $1,381,562. On average, Management trades about 117,108 units every 30 days since 2016. As of 9 September 2024 Management still owns at least 53,100 units of TELA Bio stock.

You can see the complete history of Management Opaleye stock trades at the bottom of the page.

What's Management Opaleye's mailing address?

Management's mailing address filed with the SEC is 175 Federal St, Boston, MA 02110, USA.

Insiders trading at TELA Bio

Over the last 5 years, insiders at TELA Bio have traded over $4,222,376 worth of TELA Bio stock and bought 4,343,227 units worth $46,898,981 . The most active insiders traders include Management Inc. Opaleye, Investments, Lpwong Roderic..., and Advisors Llc Orbi Med Capit.... On average, TELA Bio executives and independent directors trade stock every 18 days with the average trade being worth of $139,070. The most recent stock trade was executed by Advisors Llc Orbi Med Capit... on 28 June 2024, trading 428,300 units of TELA stock currently worth $2,021,576.

What does TELA Bio do?

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Complete history of Management Opaleye stock trades at Ocular Therapeutix Inc, TRACON Pharmaceuticals Inc, Protara Therapeutics Inc, Harrow Health, Eton Pharmaceuticals, and TELA Bio

TELA Bio executives and stock owners

TELA Bio executives and other stock owners filed with the SEC include:

• Antony Koblish,
  President, Chief Executive Officer, Co-Founder, Director
• Maarten Persenaire,
  Co-Founder, Chief Medical Officer
• Ellis Greenhalgh,
  Chief Technology Officer
• Antony Koblish,
  Co-founder, Pres, CEO & Director
• Dr. E. Skott Greenhalgh Ph.D.,
  Chief Technology Officer
• kurt Azarbarzin,
  Independent Director
• Vince Burgess,
  Independent Director
• Federica OBrien,
  Independent Director
• Adele Oliva,
  Independent Director
• Lisa Colleran,
  Independent Director
• Peter Murphy,
  Chief Commercial Officer
• Nora Brennan,
  Chief Financial Officer
• Douglas Evans,
  Independent Chairman of the Board
• D. Taylor Ocasio,
  Gen. Counsel
• Francis Michael Conway,
  VP of Fin., Treasurer & Assistant Sec.
• Peter C. Murphy,
  Chief Commercial Officer
• Paul Talmo,
  Chief Strategic Officer
• Michael Leonard,
  Sr. VP of Operations, Quality & Regulatory
• Jennifer Lou Armstrong,
  Sr. VP of HR
• Christopher H. Smith,
  Sr. VP of Sales
• Megan Smeykal,
  VP, Corp. Controller, Chief Accounting Officer & Principal Accounting Officer
• Roberto E. Cuca J.D.,
  CFO & COO
• Bio Ventures Ii Lp Quaker B...,
  
• Ronald J. Jr.Pacira Bio Sci...,
  
• Ashley Friedman,
  Director
• Investments, Lpwong Roderic...,
  
• Matt Zuga,
  Director
• Federica F. O'brien,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Healthcare Partners Fund 2,...,
  
• John Nosenzo,
  Director
• Roberto Cuca,
  COO and CFO
• Megan Smeykal,
  Chief Accounting Officer
• Paul Talmo,
  Chief Technology Officer
• Management Inc. Opaleye,
  
• Jeffrey Blizard,
  Director
• Gregory A. Firestone,
  Chief Commercial Officer